The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant efficacy in clinical trials for managing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a significant substantial decrease in body mass and benefit metabolic healt